MetaCap

Lexicon Pharmaceuticals Inc. Company Profile

NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.53-0.14 (-8.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Lexicon Pharmaceuticals at a glance

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in The Woodlands, TX. Lexicon Pharmaceuticals is led by Dr. Michael S. Exton Ph.D. and employs about 81 people. At a market capitalization of $681.2 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001062822, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Lexicon Pharmaceuticals do?

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Business description based on the company's public filings.

Company information

Legal name
Lexicon Pharmaceuticals Inc.
Ticker
NASDAQ: LXRX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael S. Exton Ph.D.
Employees
81
Headquarters
2445 Technology Forest Boulevard, The Woodlands, TX, United States
Phone
281 863 3000
Market cap
$681.21M
SEC CIK
0001062822
Latest annual report
10-K · Mar 5, 2026

Companies similar to Lexicon Pharmaceuticals

LXRX peer companies
CompanyPrice% ChgMarket capCompare
APMDApnimed Inc.16.09-6.70%$669.84Mvs LXRX
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs LXRX
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs LXRX
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs LXRX
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs LXRX
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs LXRX
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs LXRX
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs LXRX

Related